Clinical significance of serum pulmonary surfactant proteins A and D for the early detection of radiation pneumonitis

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 2, 2001, Pages 301-307

  Sasaki, Ryohei ^a   Soejima, Toshinori ^a   Matsumoto, Akira ^a   Maruta, Tsutomu ^a   Yamada, Kazunari ^a   Ota, Yosuke ^a   Kawabe, Tetsuya ^a   Nishimura, Hideki ^a   Sakai, Eiro ^b   Ejima, Yasuo ^c   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kakogawa Municipal Hospital   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

Author keywords

Lung cancer; Radiation pneumonitis; Radiation therapy; Serum marker; Surfactant protein

Indexed keywords

PATIENT MONITORING; PROTEINS; RADIATION; SURFACE ACTIVE AGENTS; TOXICITY;

RADIATION PNEUMONITIS (RP);

ONCOLOGY;

BIOCHEMICAL MARKER; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; LUNG SURFACTANT; LUNG SURFACTANT PROTEIN A; LUNG SURFACTANT PROTEIN D; MITOMYCIN C; UNCLASSIFIED DRUG; VINDESINE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LUNG CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION PNEUMONIA; TECHNIQUE;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; FEMALE; GLYCOPROTEINS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEOLIPIDS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; PULMONARY SURFACTANTS; RADIATION PNEUMONITIS; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS;

EID: 0035370767     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01591-1     Document Type: Article

References (31)

1. Gross N.J. Pulmonary effects of radiation therapy. Ann Intern Med. 86:(1):1977;81-92.
2. Movsas B., Raffin T.A., Epstein A.H., et al. Pulmonary radiation injury. Chest. 111:(4):1997;1061-1076.
3. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11 . J Clin Oncol. 8:(9):1990;1543-1555.
4. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13:(2):1995;452-458.
5. Murakami M., Kuroda Y., Nakajima T., et al. Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys. 45:(2):1999;277-284.
6. Shapiro D.L., Finkelstein J.N., Rubin P., et al. Sequential effects of irradiation on the pulmonary surfactant system. Int J Radiat Oncol Biol Phys. 8:(5):1982;879-882.
7. Rubin P., Siemann D.W., Shapiro D.L., et al. Surfactant release as an early measure of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 9:(11):1983;1669-1673.
8. Rubin P., Finkelstein J.N., Siemann D.W., et al. Predictive biochemical assays for late radiation effects. Int J Radiat Oncol Biol Phys. 12:(4):1986;469-476.
9. Rubin P., McDonald S., Maasilta P., et al. Serum markers for prediction of pulmonary radiation syndromes. Part I: Surfactant apoprotein . Int J Radiat Oncol Biol Phys. 17:(3):1989;553-558.
10. Rubin P., Finkelstein J., Shapiro D., et al. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes Interrelationship between the alveolar macrophage and the septal fibroblast . Int J Radiat Oncol Biol Phys. 24:(1):1992;93-101.
11. Kuroki Y., Voelker D.R. Pulmonary surfactant proteins. J Biol Chem. 269:1994;25943-25946.
12. Kremlev SG, Phelps DS. Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production. Am J Physiol 1994;267(6 Pt 1):L712-719.
13. Weissbach S, Neuendank A, Pettersson M; et al. Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages. Am J Physiol 1994;267(6 Pt 1):L660-666.
14. Kuan S.F., Rust K., Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest. 90:(1):1992;97-106.
15. Nagae H., Takahashi H., Kuroki Y., et al. Enzyme-linked immunosorbent assay using F(ab′)2 fragment for the detection of human pulmonary surfactant protein D in sera. Clin Chim Acta. 266:(2):1997;157-171.
16. Inoue T., Matsuura E., Nagata A., et al. Enzyme-linked immunosorbent assay for human pulmonary surfactant protein D. J Immunol Methods. 173:(2):1994;157-164.
17. Kuroki Y., Dempo K., Akino T., et al. Immunohistochemical study of human pulmonary surfactant apoproteins with monoclonal antibodies. Pathologic application for hyaline membrane disease. Am J Pathol. 124:(1):1986;25-33.
18. Kuroki Y., Takahashi H., Chiba H., et al. Surfactant proteins A and D Disease markers . Biochim Biophys Acta. 1408:(2-3):1998;334-345.
19. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond). 227:1970;680-685.
20. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy . Int J Radiat Oncol Biol Phys. 47:(1):2000;13-47.
21. McDonald S, Rubin P, Maasilta P. Response of normal lung to irradiation. Tolerance doses/tolerance volumes in pulmonary radiation syndromes. Front Radiat Ther Oncol 1989;23:255-276,299-301.
22. King R.J., Clements J.A. Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol. 223:(3):1972;715-726.
23. Kalina M., Mason R.J., Shannon J.M. Surfactant protein C is expressed in alveolar type II cells but not in Clara cells of rat lung. Am J Respir Cell Mol Biol. 6:(6):1992;594-600.
24. Rinaldo J.E., Rogers R.M. Adult respiratory-distress syndrome Changing concepts of lung injury and repair . N Engl J Med. 306:(15):1982;900-909.
25. Baker C.S., Evans T.W., Randle B.J., et al. Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet. 353:(9160):1999;1232-1237.
26. Sporn M.B., Roberts A.B. Transforming growth factor-beta Recent progress and new challenges . J Cell Biol. 119:(5):1992;1017-1021.
27. Border W.A., Ruoslahti E. Transforming growth factor-beta in disease The dark side of tissue repair . J Clin Invest. 90:(1):1992;1-7.
28. Krishnan E.C., Krishnan L., Jewell B., et al. Dose-dependent radiation effect on microvasculature and repair. J Natl Cancer Inst. 79:(6):1987;1321-1325.
29. Anscher M.S., Kong F.M., Marks L.B., et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys. 37:(2):1997;253-258.
30. Anscher M.S., Kong F.M., Andrews K., et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 41:(5):1998;1029-1035.
31. Kohno N., Hamada H., Fujioka S., et al. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest. 102:(1):1992;117-122.